Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement.
作者信息
Kojima Minoru, Amaki Jun, Ogiya Daisuke, Ando Kiyoshi, Nakamura Naoya
机构信息
Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan.
出版信息
J Clin Exp Hematop. 2020 Jun 20;60(2):60-61. doi: 10.3960/jslrt.20004. Epub 2020 May 13.
Abstract
摘要
相似文献
1
Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement.剂量调整的EPOCH-R方案用于新诊断的伴有MYC重排的弥漫性大B细胞淋巴瘤患者。
J Clin Exp Hematop. 2020 Jun 20;60(2):60-61. doi: 10.3960/jslrt.20004. Epub 2020 May 13.
2
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.剂量调整的EPOCH-R方案（依托泊苷、泼尼松、长春新碱、环磷酰胺、阿霉素和利妥昔单抗）用于治疗未经治疗的伴有MYC重排的侵袭性弥漫性大B细胞淋巴瘤：一项前瞻性、多中心、单臂2期研究。
Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7.
3
MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.弥漫性大B细胞淋巴瘤中的MYC基因重排在剂量调整的EPOCH-R治疗后并不会导致更差的预后。
Leuk Lymphoma. 2018 Feb;59(2):505-508. doi: 10.1080/10428194.2017.1339882. Epub 2017 Jun 22.
4
The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.弥漫性大 B 细胞淋巴瘤中 MYC 改变的谱。
Acta Haematol. 2020;143(6):520-528. doi: 10.1159/000505892. Epub 2020 Feb 19.
5
Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?回击淋巴瘤：现代诊断如何识别高危弥漫性大 B 细胞淋巴瘤亚群并改变治疗方法？
Cancer. 2019 Sep 15;125(18):3111-3120. doi: 10.1002/cncr.32145. Epub 2019 Jul 9.
6
CD56-positive diffuse large B-cell lymphoma/leukemia with double-hit and multiple gene mutations: an indicator of poor prognosis?CD56 阳性弥漫性大 B 细胞淋巴瘤/白血病伴双打击和多个基因突变：预后不良的指标？
J Int Med Res. 2020 May;48(5):300060520918087. doi: 10.1177/0300060520918087.
7
Genetics and diffuse large B-Cell lymphoma.遗传学与弥漫性大B细胞淋巴瘤
R I Med J (2013). 2015 Nov 2;98(11):23-6.
8
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study.高级别 B 细胞淋巴瘤，非特指型：一项多机构回顾性研究。
Blood Adv. 2023 Nov 14;7(21):6381-6394. doi: 10.1182/bloodadvances.2023009731.
9
[Significance and application of c-myc in diffuse large B-cell lymphoma].c-myc在弥漫性大B细胞淋巴瘤中的意义及应用
Zhonghua Bing Li Xue Za Zhi. 2013 Sep;42(9):638-40.
10
Inferior survival in high-grade B-cell lymphoma with and and/or rearrangements is not associated with gene rearrangements.伴有 和/或 重排的高级别 B 细胞淋巴瘤患者的生存情况较差，但与 基因重排无关。
Haematologica. 2018 Nov;103(11):1899-1907. doi: 10.3324/haematol.2018.190157. Epub 2018 Jun 14.
引用本文的文献
1
DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction.DA-EPOCH-R 疗法治疗肾功能障碍患者伴有 MYC 和 BCL2 及/或 BCL6 重排的高级别 B 细胞淋巴瘤。
J Clin Exp Hematop. 2021 Mar 18;61(1):42-47. doi: 10.3960/jslrt.20043. Epub 2021 Feb 6.
本文引用的文献
1
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.剂量调整的EPOCH-R方案（依托泊苷、泼尼松、长春新碱、环磷酰胺、阿霉素和利妥昔单抗）用于治疗未经治疗的伴有MYC重排的侵袭性弥漫性大B细胞淋巴瘤：一项前瞻性、多中心、单臂2期研究。
Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7.
2
Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.仅MYC基因重排而非扩增与弥漫性大B细胞淋巴瘤和无法分类的B细胞淋巴瘤患者的不良预后相关。
Br J Haematol. 2016 Nov;175(4):631-640. doi: 10.1111/bjh.14282. Epub 2016 Jul 29.
3
Double hit lymphoma: the MD Anderson Cancer Center clinical experience.双打击淋巴瘤：MD 安德森癌症中心的临床经验。
Br J Haematol. 2014 Sep;166(6):891-901. doi: 10.1111/bjh.12982. Epub 2014 Jun 18.
4
Low-intensity therapy in adults with Burkitt's lymphoma.成人伯基特淋巴瘤的低强度治疗。
N Engl J Med. 2013 Nov 14;369(20):1915-25. doi: 10.1056/NEJMoa1308392.
5
Two-weekly dose-adjusted (DA)-EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma.两周一次剂量调整（DA）-EPOCH 样化疗联合高剂量地塞米松和利妥昔单抗（DA-EDOCH14-R）治疗不良预后未经治疗的弥漫性大 B 细胞淋巴瘤。
Br J Haematol. 2013 Feb;160(4):510-4. doi: 10.1111/bjh.12144. Epub 2012 Dec 11.
6
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.癌症和白血病协作组 B 针对未经治疗的弥漫性大 B 细胞淋巴瘤的 DA-EPOCH-rituximab 多中心研究，通过分子亚型分析其结果。
Haematologica. 2012 May;97(5):758-65. doi: 10.3324/haematol.2011.056531. Epub 2011 Dec 1.
7
MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.MYC基因重排与接受R-CHOP化疗的弥漫性大B细胞淋巴瘤患者的不良预后相关。
Blood. 2009 Oct 22;114(17):3533-7. doi: 10.1182/blood-2009-05-220095. Epub 2009 Aug 24.
8
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.使用组织芯片通过免疫组织化学法对弥漫性大B细胞淋巴瘤进行分子分类的确认。
Blood. 2004 Jan 1;103(1):275-82. doi: 10.1182/blood-2003-05-1545. Epub 2003 Sep 22.
Zotero 插件